MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 05-30-2026
Enzo Biochem DPO Ratio 2011-2026 | ENZ
Annual DPO Ratio Enzo Biochem
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.3 | 74.5 | 112 | 47.3 | 55 | 52.8 | 60 | 62 | 62.9 | 58.4 | 55.5 | 56.5 | 58.8 | 53.3 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 112 | 47.3 | 61.6 |
Quarterly DPO Ratio Enzo Biochem
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.1 | 351 | 31.5 | 32.8 | - | 30.2 | 34.6 | 58.1 | - | 209 | 148 | 165 | - | 34.4 | 30.2 | 42 | 22.9 | 44.4 | 53.9 | 44.5 | 27.6 | 44.3 | 50.7 | 49.9 | 21.5 | 50.8 | 48.9 | 53.4 | 28 | 63.5 | - | 58.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 351 | 21.5 | 66.3 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B |  USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
14.7 | $ 202.97 | -0.04 % | $ 22.5 B | USA |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
4.24 K | $ 4.1 | -4.43 % | $ 5.45 M | USA |
 |
Fulgent Genetics
FLGT
|
35.2 | $ 18.7 | 0.08 % | $ 576 M | USA |
 |
Castle Biosciences
CSTL
|
65.8 | $ 20.51 | -0.92 % | $ 595 M | USA |
 |
Aspira Women's Health
AWH
|
189 | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
196 | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
33 | $ 1.6 | -3.03 % | $ 7.08 M | USA |
 |
Illumina
ILMN
|
57.1 | $ 161.5 | 0.33 % | $ 25 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
48.6 | $ 129.51 | -1.61 % | $ 16.2 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 22.75 | -0.96 % | $ 1.21 B | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
11 | $ 146.68 | 0.34 % | $ 11.5 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 146.92 | 1.58 % | $ 23.6 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
National Research Corporation
NRC
|
10.1 | $ 18.78 | -0.05 % | $ 420 M | USA |
 |
Natera
NTRA
|
17.9 | $ 211.42 | -0.31 % | $ 28.9 B | USA |
 |
Lantheus Holdings
LNTH
|
23.6 | $ 104.16 | -0.34 % | $ 7.03 B | USA |
 |
Pacific Biosciences of California
PACB
|
59.7 | $ 1.33 | 1.15 % | $ 399 M | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 190.12 | 1.39 % | $ 9.42 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 470.72 | 0.72 % | $ 13.6 B | USA |
 |
Exact Sciences Corporation
EXAS
|
49.2 | - | - | $ 19.8 B | USA |
 |
NeoGenomics
NEO
|
19.7 | $ 11.12 | -0.31 % | $ 1.42 B | USA |
 |
Myriad Genetics
MYGN
|
45.9 | $ 4.26 | -1.59 % | $ 394 M | USA |
 |
Personalis
PSNL
|
65.7 | $ 9.7 | 1.15 % | $ 866 M | USA |
 |
Twist Bioscience Corporation
TWST
|
12.5 | $ 79.05 | 3.78 % | $ 4.73 B | USA |
 |
Senseonics Holdings
SENS
|
68 | $ 7.34 | 2.16 % | $ 306 M | USA |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
Soleno Therapeutics
SLNO
|
1.44 K | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
32.4 | $ 2.05 | - | $ 4.71 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
31.5 | $ 265.64 | -0.2 % | $ 22.1 B | USA |
 |
Thermo Fisher Scientific
TMO
|
49.3 | $ 473.34 | 0.95 % | $ 178 B | USA |
 |
Trinity Biotech plc
TRIB
|
163 | $ 0.65 | - | $ 233 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
62.7 | $ 9.24 | 1.54 % | $ 2 B | USA |
 |
Invitae Corporation
NVTA
|
69 | - | - | $ 21.2 M | USA |